Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009

Shio Shin Jean, Wen Sen Lee, Kuan Jen Bai, Kwok Woon Yu, Chin Wang Hsu, Chun Hsing Liao, Feng Yi Chang, Wen Chien Ko, Jiunn Jong Wu, Yen Hsu Chen, Yao Shen Chen, Jien Wei Liu, Min Chi Lu, Cheng Yi Liu, Ray Jade Chen, Po Ren Hsueh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

To investigate the evolutionary trends in non-susceptibility of carbapenems against the isolates of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae from patients hospitalized in intensive care units (ICUs) of major teaching hospitals throughout Taiwan during 2005-2009, we applied the breakpoints of MICs recommended by Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing in 2013. Escalations in imipenem MIC levels for overall E. coli and E. cloacae isolates and extended-spectrum β-lactamase (ESBL)-producing K. pneumoniae isolates were noted during this period. The overall MIC levels against imipenem and meropenem for subgroups of ESBL producers of 3 Enterobacteriaceae species were significantly higher than those of respective overall groups in 2007 and 2009. Compared with meropenem, we found that significant evidence of imipenem MIC creep and evidence of extraordinarily high rates of non-susceptibility to ertapenem among isolates of 3 species in 2009 existed. The prominent rises in rates of ertapenem non-susceptibility for ESBL-producing E. coli and K. pneumoniae during 2005-2009 and rate of ESBL positivity for E. cloacae between 4. years were notably found. Based on our findings, ertapenem should be used cautiously in management of the ICU infections caused by these potentially ESBL-producing Enterobacteriaceae isolates in Taiwan.

Original languageEnglish
Pages (from-to)290-295
Number of pages6
JournalDiagnostic Microbiology and Infectious Disease
Volume81
Issue number4
DOIs
Publication statusPublished - Apr 1 2015

Fingerprint

meropenem
Enterobacter cloacae
Carbapenems
Imipenem
Klebsiella pneumoniae
Taiwan
Intensive Care Units
Enterobacteriaceae
Escherichia coli
Teaching Hospitals
Infection
ertapenem

Keywords

  • Carbapenem
  • Enterobacteriaceae
  • Extended-spectrum β-lactamase
  • Intensive care unit
  • Non-susceptibility

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009. / Jean, Shio Shin; Lee, Wen Sen; Bai, Kuan Jen; Yu, Kwok Woon; Hsu, Chin Wang; Liao, Chun Hsing; Chang, Feng Yi; Ko, Wen Chien; Wu, Jiunn Jong; Chen, Yen Hsu; Chen, Yao Shen; Liu, Jien Wei; Lu, Min Chi; Liu, Cheng Yi; Chen, Ray Jade; Hsueh, Po Ren.

In: Diagnostic Microbiology and Infectious Disease, Vol. 81, No. 4, 01.04.2015, p. 290-295.

Research output: Contribution to journalArticle

Jean, Shio Shin ; Lee, Wen Sen ; Bai, Kuan Jen ; Yu, Kwok Woon ; Hsu, Chin Wang ; Liao, Chun Hsing ; Chang, Feng Yi ; Ko, Wen Chien ; Wu, Jiunn Jong ; Chen, Yen Hsu ; Chen, Yao Shen ; Liu, Jien Wei ; Lu, Min Chi ; Liu, Cheng Yi ; Chen, Ray Jade ; Hsueh, Po Ren. / Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009. In: Diagnostic Microbiology and Infectious Disease. 2015 ; Vol. 81, No. 4. pp. 290-295.
@article{333f6812305b4330a5e4a5d7f93f1f41,
title = "Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009",
abstract = "To investigate the evolutionary trends in non-susceptibility of carbapenems against the isolates of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae from patients hospitalized in intensive care units (ICUs) of major teaching hospitals throughout Taiwan during 2005-2009, we applied the breakpoints of MICs recommended by Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing in 2013. Escalations in imipenem MIC levels for overall E. coli and E. cloacae isolates and extended-spectrum β-lactamase (ESBL)-producing K. pneumoniae isolates were noted during this period. The overall MIC levels against imipenem and meropenem for subgroups of ESBL producers of 3 Enterobacteriaceae species were significantly higher than those of respective overall groups in 2007 and 2009. Compared with meropenem, we found that significant evidence of imipenem MIC creep and evidence of extraordinarily high rates of non-susceptibility to ertapenem among isolates of 3 species in 2009 existed. The prominent rises in rates of ertapenem non-susceptibility for ESBL-producing E. coli and K. pneumoniae during 2005-2009 and rate of ESBL positivity for E. cloacae between 4. years were notably found. Based on our findings, ertapenem should be used cautiously in management of the ICU infections caused by these potentially ESBL-producing Enterobacteriaceae isolates in Taiwan.",
keywords = "Carbapenem, Enterobacteriaceae, Extended-spectrum β-lactamase, Intensive care unit, Non-susceptibility",
author = "Jean, {Shio Shin} and Lee, {Wen Sen} and Bai, {Kuan Jen} and Yu, {Kwok Woon} and Hsu, {Chin Wang} and Liao, {Chun Hsing} and Chang, {Feng Yi} and Ko, {Wen Chien} and Wu, {Jiunn Jong} and Chen, {Yen Hsu} and Chen, {Yao Shen} and Liu, {Jien Wei} and Lu, {Min Chi} and Liu, {Cheng Yi} and Chen, {Ray Jade} and Hsueh, {Po Ren}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.diagmicrobio.2014.09.027",
language = "English",
volume = "81",
pages = "290--295",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009

AU - Jean, Shio Shin

AU - Lee, Wen Sen

AU - Bai, Kuan Jen

AU - Yu, Kwok Woon

AU - Hsu, Chin Wang

AU - Liao, Chun Hsing

AU - Chang, Feng Yi

AU - Ko, Wen Chien

AU - Wu, Jiunn Jong

AU - Chen, Yen Hsu

AU - Chen, Yao Shen

AU - Liu, Jien Wei

AU - Lu, Min Chi

AU - Liu, Cheng Yi

AU - Chen, Ray Jade

AU - Hsueh, Po Ren

PY - 2015/4/1

Y1 - 2015/4/1

N2 - To investigate the evolutionary trends in non-susceptibility of carbapenems against the isolates of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae from patients hospitalized in intensive care units (ICUs) of major teaching hospitals throughout Taiwan during 2005-2009, we applied the breakpoints of MICs recommended by Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing in 2013. Escalations in imipenem MIC levels for overall E. coli and E. cloacae isolates and extended-spectrum β-lactamase (ESBL)-producing K. pneumoniae isolates were noted during this period. The overall MIC levels against imipenem and meropenem for subgroups of ESBL producers of 3 Enterobacteriaceae species were significantly higher than those of respective overall groups in 2007 and 2009. Compared with meropenem, we found that significant evidence of imipenem MIC creep and evidence of extraordinarily high rates of non-susceptibility to ertapenem among isolates of 3 species in 2009 existed. The prominent rises in rates of ertapenem non-susceptibility for ESBL-producing E. coli and K. pneumoniae during 2005-2009 and rate of ESBL positivity for E. cloacae between 4. years were notably found. Based on our findings, ertapenem should be used cautiously in management of the ICU infections caused by these potentially ESBL-producing Enterobacteriaceae isolates in Taiwan.

AB - To investigate the evolutionary trends in non-susceptibility of carbapenems against the isolates of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae from patients hospitalized in intensive care units (ICUs) of major teaching hospitals throughout Taiwan during 2005-2009, we applied the breakpoints of MICs recommended by Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing in 2013. Escalations in imipenem MIC levels for overall E. coli and E. cloacae isolates and extended-spectrum β-lactamase (ESBL)-producing K. pneumoniae isolates were noted during this period. The overall MIC levels against imipenem and meropenem for subgroups of ESBL producers of 3 Enterobacteriaceae species were significantly higher than those of respective overall groups in 2007 and 2009. Compared with meropenem, we found that significant evidence of imipenem MIC creep and evidence of extraordinarily high rates of non-susceptibility to ertapenem among isolates of 3 species in 2009 existed. The prominent rises in rates of ertapenem non-susceptibility for ESBL-producing E. coli and K. pneumoniae during 2005-2009 and rate of ESBL positivity for E. cloacae between 4. years were notably found. Based on our findings, ertapenem should be used cautiously in management of the ICU infections caused by these potentially ESBL-producing Enterobacteriaceae isolates in Taiwan.

KW - Carbapenem

KW - Enterobacteriaceae

KW - Extended-spectrum β-lactamase

KW - Intensive care unit

KW - Non-susceptibility

UR - http://www.scopus.com/inward/record.url?scp=84925115108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925115108&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2014.09.027

DO - 10.1016/j.diagmicrobio.2014.09.027

M3 - Article

C2 - 25600841

AN - SCOPUS:84925115108

VL - 81

SP - 290

EP - 295

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 4

ER -